Peg‐interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti‐HBV efficacy and long‐term survival among HBV DNA‐positive hepatocellular carcinoma patients after hepatectomy/ablation. Issue 4 (11th December 2019)

• Record Type: Journal Article
• Authors: Qi, Wenqian; Zhang, Qian; Xu, Yan; Wang, Xu; Yu, Fan; Zhang, Yonggui; Zhao, Ping; Guo, Honghua; Zhou, Changyu; Wang, Zhe; Sun, Yu; Liu, Lin; Xuan, Wei; Wang, Jiangbin
• Is Part Of: Journal of viral hepatitis. Volume 27:Issue 4(2020)
• Page Start: 387
• Page End: 396
• Publication Date: 2019-12-11
• Subjects: drug combinations -- hepatitis B virus -- hepatocellular carcinoma -- interferon -- prognosis; Hepatitis, Viral -- Periodicals; Hepatitis, Viral, Animal; Hepatitis, Viral, Human; 616.3623
• DOI: 10.1111/jvh.13236
• Languages: English
• ISSNs: 1352-0504

Abstract

Abstract: Antiviral therapy has been shown to improve the prognosis of hepatitis B virus (HBV) DNA‐positive hepatocellular carcinoma (HCC) after radical treatment, but antiviral treatments require further optimization. This study aimed to evaluate the efficacies of different antiviral strategies with HCC patients after hepatectomy/ablation. This prospective, randomized, controlled and multi‐centre trial enrolled HBV DNA‐positive primary HCC patients after hepatectomy/ablation between January 2007 and January 2009. Patients were divided into four groups: early combination (entecavir plus Peg‐interferon [IFN]α‐2a co‐administration during year 1); late combination (addition of Peg‐IFNα‐2a for 48 weeks after 1 year of entecavir); nucleos(t)ide analogue[NA] monotherapy; and non‐antiviral treatment. Primary endpoints included recurrence‐free survival and overall survival. A total of 447 patients were enrolled. The 2‐year and 8‐year recurrence‐free survival and 8‐year overall survival rates were significantly higher in the early combination group than in the other two antiviral groups ( P < .05). After 48‐week treatment, more patients achieved an HBsAg reduction >1500 IU/mL and the mean HBsAg level was significantly lower in the early combination group compared with the late combination and NA monotherapy groups ( P < .05). Multivariate analysis showed that early combination therapy and a reduction in HBsAg by >1500 IU/mL after 48 weeks of therapy correlated with reduced mortality and disease recurrence. Early introduction of combination antiviral treatment may represent a more effective therapeutic strategy for patients with HBV DNA‐positive HCC after hepatectomy/ablation. A reduction in HBsAg by >1500 IU/mL after 48‐week treatment is associated with reduced mortality and disease recurrence of HBV DNA‐positive HCC patients after hepatectomy/ablation.